ORPHA:319287
Multilocular cystic renal neoplasm of low malignant potential
Also known as: MCRCC · Multilocular clear cell adenocarcinoma · Multilocular clear cell carcinoma · Multilocular clear cell renal cell adenocarcinoma · Multilocular clear cell renal cell carcinoma · Multilocular cystic renal cell adenocarcinoma · Multilocular cystic renal cell carcinoma
Publications
488
81.9th percentile
Trials
0
Interventional, condition-specific
Researchers
1,112
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
Multilocular cystic renal neoplasm of low malignant potential is a rare subtype of clear cell renal cell carcinoma with distinct pathological features of cysts lined by occasionally flattened cuboidal clear cells and septa containing aggregates of epithelial cells with clear cytoplasm, and excellent prognosis. The tumor usually presents as an asymptomatic, unilateral, solitary lesion, macroscopically consisting of numerous, fluid-filled, septated cysts of variable size. Rarely, the symptoms typically associated with renal tumors (flank pain, hematuria, palpable mass) may be present.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0003010
- UMLS:C0346249
- NCIT:C4524
Additional Mondo synonyms (9)
multilocular clear cell adenocarcinoma · multilocular clear cell carcinoma · multilocular clear cell renal cell adenocarcinoma · multilocular clear cell renal cell carcinoma · multilocular cystic clear cell renal cell neoplasm of low malignant potential · multilocular cystic renal cell adenocarcinoma · multilocular cystic renal cell cancer · multilocular cystic renal cell carcinoma · renal cystadenocarcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
488 matched papers (248 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
488
488 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
488 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
248 in the last 10 years · high confidence · 81.9th percentile (publications denominator)
Phrase hits: 488 · MeSH hits: 0
Who's working on it?
1,112
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Cheng L10 papers · 2017
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN; Department of Urology, Indiana University School of Medicine, Indianapolis, IN. Electronic address: liang_cheng@yahoo.com.
Papers in Europe PMC - 02Montironi R10 papers · 2017
Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, United Hospitals, Ancona, Italy. r.montironi@univpm.it
Papers in Europe PMC - 03Lopez-Beltran A9 papers · 2017
Unit of Anatomic Pathology, Department of Surgery, Cordoba University Medical School, Cordoba, Spain; Champalimaud Clinical Center, Lisbon, Portugal.
Papers in Europe PMC - 04Li Y6 papers · 2022
Department of Pathology, Affiliated Hospital of Jining Medical University Jining, Shandong Province, P. R. China.
Papers in Europe PMC - 05Li G5 papers · 2024
Service d'urologie-andrologie, université Jean-Monnet, hôpital Nord, CHU de Saint-Étienne, 108, avenue Albert-Raimond, 42055 Saint-Étienne cedex 2, France. grli2001@yahoo.fr
Papers in Europe PMC - 06Wang Y5 papers · 2024
Department of Pathology, Qianwei Hospital of Jilin Province, Changchun, China.
Papers in Europe PMC - 07Finelli A4 papers · 2025
Division of Urology, Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada. Electronic address: Antonio.finelli@uhn.ca.
Papers in Europe PMC - 08Gong K4 papers · 2016
Department of Urology, The First Hospital of Peking University, Institute of Urology, Peking University, Beijing 100034, China.
Papers in Europe PMC - 09Li L4 papers · 2025
Department of Pathology, Affiliated Hospital of Jining Medical University Jining, Shandong Province, P. R. China.
Papers in Europe PMC - 10Martignoni G4 papers · 2017
Anatomic Pathology, Department of Pathology, University of Verona, Verona, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Multilocular cystic renal neoplasm of low malignant potential" OR "Multilocular cystic renal neoplasm of the low malignant potential" OR "MCRCC" OR "Multilocular clear cell adenocarcinoma" OR "Multilocular clear cell carcinoma" OR "Multilocular clear cell renal cell adenocarcinoma" OR "Multilocular clear cell renal cell carcinoma" OR "Multilocular cystic renal cell adenocarcinoma" OR "Multilocular cystic renal cell carcinoma" OR "multilocular cystic clear cell renal cell neoplasm of low malignant potential" OR "multilocular cystic clear cell renal cell neoplasm of the low malignant potential" OR "multilocular cystic renal cell cancer" OR "renal cystadenocarcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Multilocular cystic renal neoplasm of low malignant potential" OR "Multilocular cystic renal neoplasm of the low malignant potential" OR "MCRCC" OR "Multilocular clear cell adenocarcinoma" OR "Multilocular clear cell carcinoma" OR "Multilocular clear cell renal cell adenocarcinoma" OR "Multilocular clear cell renal cell carcinoma" OR "Multilocular cystic renal cell adenocarcinoma" OR "Multilocular cystic renal cell carcinoma" OR "multilocular cystic clear cell renal cell neoplasm of low malignant potential" OR "multilocular cystic clear cell renal cell neoplasm of the low malignant potential" OR "multilocular cystic renal cell cancer" OR "renal cystadenocarcinoma"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T13:23:16.871Z